The 3,600 sqft facility will help develop the MIMIX sustained-release intradermal microneedle patch, which is planned for proof-of-concept trials for COVID-19 in 2022
The #1 cleanroom event returns in May and this year's conference promises to be our most impactful yet.
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.